The tricky part is that it isn't always easy to find companies you can buy and hold. The corporate landscape is ruthlessly ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

The clinical benefits of exercise-based cardiac rehabilitation have been less clear for patients with Afib. A meta-analysis ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know.

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

DelveInsight's,“ Thyroid Cancer Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 51+ ...